Nanovibronix (FEED) Financials

Note: The supplied financial statements identify the company as ENvue Medical, Inc. (ticker FEED), rather than Nanovibronix. The analysis below is based on the provided FEED data, including restated 2024 and 2025 figures.

Revenue trends remain weak. Revenue declined to $239,000 in Q2 2026 from $494,000 in Q2 2025 and $817,000 in Q2 2024. Q1 revenue also fell year over year, from $1.025 million in Q1 2025 to $653,000 in Q1 2026. The company has not established a consistent growth trend, with quarterly revenue generally below 2023 and early-2024 levels.

Profitability has deteriorated sharply. Q2 2026 produced a gross loss of $266,000, compared with a gross loss of $35,000 in Q2 2025 and gross profit of $428,000 in Q2 2024. Operating expenses increased to $5.208 million in Q2 2026 from $3.656 million in Q1 2026 and $3.941 million in Q2 2025. The resulting operating loss was $5.474 million, while net loss attributable to common shareholders reached $12.164 million after $7.265 million of preferred dividends.

Cash generation remains a major concern. Operating cash flow has been negative in every reported quarter provided since Q3 2023. The Q2 2026 operating cash outflow of $2.691 million improved from $4.312 million in Q1 2026 and $3.383 million in Q2 2025, but it still represents a significant cash drain relative to the company’s revenue base.

• Operating cash burn improved sequentially: Q2 2026 operating cash outflow decreased by approximately 38% from Q1 2026, suggesting some short-term improvement in cash management or working-capital movements.
• Financing provided near-term liquidity: The company raised $3.074 million through common equity issuance in Q2 2026, resulting in $1.594 million of net financing cash flow after a $1.480 million preferred-equity repurchase.
• Liabilities declined from the prior quarter: Total liabilities fell to $7.647 million at June 30, 2026, from $7.856 million at March 31, 2026, while short-term debt remained stable at $1.080 million.
• Capital spending remains limited: Q2 2026 purchases of property, plant and equipment were only $27,000, indicating that cash needs are driven primarily by operating losses rather than an aggressive capital-investment program.
• Other income partially offset operating losses: Q2 2026 included $603,000 of other income, helping reduce the pretax loss. However, this benefit was not enough to offset operating expenses and may not represent recurring operating performance.
• Inventory increased: Net inventory rose to $2.581 million at June 30, 2026, from $2.266 million at March 31, 2026. This could support future sales, but it also ties up cash while revenue remains subdued.
• Revenue contraction is broad and persistent: Q2 revenue fell approximately 52% year over year, and Q1 revenue declined approximately 36% year over year, indicating pressure on demand, sales execution or product volumes.
• Gross margins moved further below zero: Q2 2026 cost of revenue was more than twice revenue, producing a negative gross margin of roughly 111%. The company must improve pricing, volume and production costs before operating expenses can be supported.
• Liquidity is strained: Cash and equivalents declined to $1.084 million from $2.235 million at the end of Q1 2026 and $6.950 million at Q3 2025. Current assets of $4.818 million were below current liabilities of $7.305 million, implying a current ratio of approximately 0.66.
• Shareholder dilution and preferred claims are significant: Common stock increased from $108.052 million at Q1 2024 to $155.286 million at Q2 2026, while Q2 2026 preferred dividends of $7.265 million caused the loss attributable to common shareholders to substantially exceed the consolidated net loss. Weighted-average basic shares also rose to 6.16 million in Q2 2026 from 62,615 in Q1 2025, making per-share comparisons difficult and highlighting substantial dilution.

The balance sheet provides limited comfort. Total assets declined to $38.405 million at June 30, 2026, from $54.383 million at September 30, 2025. Approximately $32.044 million, or more than 80% of total assets, consisted of goodwill and intangible assets, leaving relatively little in cash and other readily liquid assets. Although reported equity remained positive at $30.758 million, continued losses and cash burn could require additional equity financing.

Overall, the financial trend is negative for investors. The company has shown a modest sequential improvement in operating cash burn and has maintained access to equity financing, but those positives are outweighed by declining revenue, worsening gross losses, high operating expenses, shrinking cash reserves, weak working-capital coverage and substantial dilution. A sustainable improvement in revenue and gross margins will be necessary before the company can reduce its reliance on external financing.